1. China Stocks

  2. •

    Producer manufacturing

  3. •

    Industrial machinery
Austar Lifesciences Ltd.

Austar Lifesciences Ltd.

0.02
USD
-0.05
(-71.43%)
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.38
1.72
1.22
1.31
1.07
1.59
2.05
2.53
3.93
4.21
3.44
2.93
2.99
- -
Basic EPS, GAAP
0.1
0.17
0.01
-0.04
-0.11
- -
0.02
0.06
0.54
0.17
-0.22
0.03
0.07
- -
Free Cash Flow per Basic Share
0.12
-0.19
0.09
-0.08
-0.03
-0.23
0.05
-0.03
-0.43
-0.34
-0.26
0.15
0.2
- -
Dividend per Share
- -
0.02
0.04
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.25
1.07
1.07
1.07
0.93
0.94
0.96
1.01
1.53
1.75
1.51
1.54
1.6
1.6
Tangible Book Value per Share
0.24
1.06
1.06
1.05
0.91
0.81
0.91
0.82
1.34
1.49
1.3
1.34
1.39
1.39
Basic Weighted Avg Shares
513
394
513
513
513
513
513
513
513
513
513
513
513
513
Sales/Revenue/Turnover
705
680
628
673
547
817
1,049
1,296
2,015
2,157
1,764
1,500
1,531
- -
Operating Margin (%)
10.25
12.46
0.39
-3.19
-12.6
-0.77
0.44
2.74
6
5.72
-0.51
2.41
2.2
- -
Depreciation Expense
6
8
11
12
9
10
26
32
32
37
46
53
49
- -
Net Income, GAAP
54
65
6
-19
-54
- -
8
33
277
87
-113
16
34
- -
Effective Tax Rate (%)
30.11
25.77
15.9
- -
- -
96.57
38.86
23.82
14.6
15.81
- -
35.9
31.68
- -
Profit Margin (%)
7.6
9.59
1.02
-2.78
-9.89
0.01
0.77
2.55
13.76
4.05
-6.43
1.07
2.21
- -
Working Capital
71
495
474
441
363
316
294
284
527
441
396
363
426
426
LT Debt
- -
- -
- -
- -
- -
- -
25
32
89
103
163
56
73
73
Total Equity
128
549
551
546
480
483
503
525
788
884
775
793
824
824
Return on Invested Capital (%)
- -
15.39
0.46
- -
- -
-0.08
0.01
3.96
33.73
8.88
- -
1.82
3.11
- -
Return on Capital (%)
- -
18.18
1.38
- -
- -
0.03
2.01
6.32
37
10.65
- -
2.4
3.64
- -
Return on Common Equity (%)
- -
19.25
1.16
-3.4
-10.56
0.02
1.66
6.54
42.51
10.39
-13.59
2.06
4.19
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
346
281
270
LT Borrowings
25
62
63
LT Finance Leases
31
15
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
513
513
513
Market Capitalization
- -
261
- -

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1,552
1,499
1,614
Cash, Cash Equivalents & STI
168
166
227
Accounts Receivable, Net
432
337
362
Inventories
238
229
280
Total Current Liabilities
1,189
1,096
1,188
Payables & Accruals
- -
- -
- -
ST Debt
346
281
270
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.24%
11.26%
3.86%
Free Cash Flow
131.32%
239.39%
35.23%
Net Income, GAAP
790.35%
87.13%
110.24%
Sales/Revenue/Turnover
12.12%
6.28%
2.02%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1,764
2024
- -
- -
1,500
2025
- -
- -
1,531

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.22
2024
- -
- -
0.03
2025
- -
- -
0.07

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kwok Keung Ho
Full Time Employees
1,468
Sector
Producer manufacturing
Industry
Industrial machinery
Address
No. 1018, Changning Road Shanghai SH China
IPO Date
Nov 7, 2014
Website
austar.com.hk
Similar Companies
Applied Materials, Inc. (NASDAQ:AMAT)
Oklo Inc. (NYSE:OKLO)
Lam Research Corporation (NASDAQ:LRCX)
Tokyo Electron Ltd. (TSE:8035)
Welspun Corp Limited (NSE:WELCORP)
Symbotic Inc. (NASDAQ:SYM)
Business
Austar Lifesciences Limited Austar Lifesciences Limited (6118.HK) is an investment holding company engaged in providing integrated engineering solutions, manufacturing, and distributing pharmaceutical equipment and consumables to pharmaceutical manufacturers and research institutes primarily in Mainland China. The company operates through three main segments: Integrated Process and Packaging Equipment & Systems (IPS), which offers clean utilities, biopharma process equipment, aseptic freeze-drying, filling and visual inspection solutions, formulation technology, cleaning, sterilization and disinfection systems, containment technology, clean rooms, HVAC/EMS/BMS, and quality/measurement & analytics; Consulting, Digitalization and Construction (CDC), encompassing project management, engineering design, GMP compliance review, facility management, validation services, lifecycle digital solutions, and regulatory compliance consulting; and Life Science Equipment and Consumables (SIC), including bioprocess consumables, laboratory solutions, biosafety technology, and environmental monitoring systems. Founded in 1991 and headquartered in Shanghai, China, Austar Lifesciences serves the life sciences industry with turnkey solutions across sterile drug production, bioprocessing, contamination control, and operational excellence, featuring brands such as H+E Pharma, BIOSYSTEC, STERIS-AUSTAR, and ROTA-AUSTAR. Recent developments include showcasing at CPHI Frankfurt 2025 and CPHI & PMEC India 2025, launching end-to-end pre-filled syringe (PFS) solutions from filling to inspection and packaging, providing consulting and engineering design for stem cell, oncolytic virus, polypeptide, and insulin projects, and completing the acquisition of full control in its STERIS-AUSTAR joint venture through subsidiary Austar Equipment buying out the partner's 51% stake.